News
Market Data
Register to chat with like-minded investors on our interactive forums.
Sanofi: Information concerning the total number of voting rights and shares - July 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...
Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant Sarclisa (isatuximab) in...
Communiqué : Le traitement d’induction par Sarclisa a démontré une amélioration significative de la survie sans progression chez les patients atteints d’un myélome multiple nouvellement...
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant Sarclisa...
Press Release: Online availability of Sanofi’s half-year financial report for 2024 Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that...
Communiqué de presse : Mise en ligne du rapport financier semestriel 2024 de Sanofi Mise en ligne du rapport financier semestriel 2024 de Sanofi Paris, le 25 juillet 2024. Sanofi annonce...
Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available...
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded Paris, July 25, 2024 Q2...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
